Suppr超能文献

细胞毒性T淋巴细胞识别的BALB/c RL雄性1白血病独特抗原肽pRL1的鉴定及其与Akt癌基因的关系。

Identification of a unique antigen peptide pRL1 on BALB/c RL male 1 leukemia recognized by cytotoxic T lymphocytes and its relation to the Akt oncogene.

作者信息

Uenaka A, Ono T, Akisawa T, Wada H, Yasuda T, Nakayama E

机构信息

Department of Tumor Immunology, Center for Adult Diseases, Osaka, Japan.

出版信息

J Exp Med. 1994 Nov 1;180(5):1599-607. doi: 10.1084/jem.180.5.1599.

DOI:10.1084/jem.180.5.1599
PMID:7964448
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC2191716/
Abstract

BALB/c radiation leukemia RL male 1 is an immunogenic tumor. We established bulk and cloned cytotoxic T lymphocyte (CTL) lines from regressor (BALB/c x C57BL/6)F1 (CB6F1) spleen cells that recognized RL male 1 specifically. We then obtained antigen peptide recognized by CTL from RL male 1 by acid extraction. Analysis of the acid extract by reversed-phase high performance liquid chromatography (HPLC) on a semipreparative C18 column revealed that fractions eluted in 23 min (peak a) and 26 min (peak b) showed sensitization activity on the P815 target for specific CTL. On further purification of these fractions by HPLC and direct sequencing by Edman degradation, we identified the CTL-recognizing RL male 1 peptide pRL1a (IPGLPLSL) in peak a and its possible precursor peptide pRL1b (SIIPGLPLSL) in peak b. Sequence homology indicated that these peptides were derived from the 5' untranslated region of c-akt oncogene.

摘要

BALB/c辐射白血病RL雄性1是一种免疫原性肿瘤。我们从消退型（BALB/c×C57BL/6）F1（CB6F1）脾细胞中建立了大量和克隆的细胞毒性T淋巴细胞（CTL）系，这些细胞系能特异性识别RL雄性1。然后，我们通过酸提取从RL雄性1中获得了被CTL识别的抗原肽。在半制备C18柱上通过反相高效液相色谱（HPLC）对酸提取物进行分析，结果显示在23分钟（峰a）和26分钟（峰b）洗脱的馏分对特异性CTL的P815靶标具有致敏活性。通过HPLC对这些馏分进行进一步纯化，并通过埃德曼降解法进行直接测序，我们在峰a中鉴定出识别RL雄性1的CTL肽pRL1a（IPGLPLSL），在峰b中鉴定出其可能的前体肽pRL1b（SIIPGLPLSL）。序列同源性表明这些肽源自c-akt癌基因的5'非翻译区。

相似文献

1
Identification of a unique antigen peptide pRL1 on BALB/c RL male 1 leukemia recognized by cytotoxic T lymphocytes and its relation to the Akt oncogene.细胞毒性T淋巴细胞识别的BALB/c RL雄性1白血病独特抗原肽pRL1的鉴定及其与Akt癌基因的关系。
J Exp Med. 1994 Nov 1;180(5):1599-607. doi: 10.1084/jem.180.5.1599.
2
Expression of multiple unique rejection antigens on murine leukemia BALB/c RLmale symbol1 and the role of dominant Akt antigen for tumor escape.多种独特排斥抗原在小鼠白血病BALB/c RLmale symbol1上的表达以及显性Akt抗原在肿瘤逃逸中的作用。
J Immunol. 1999 Jun 1;162(11):6420-5.
3
Rejection antigen peptides on BALB/c RL male 1 leukemia recognized by cytotoxic T lymphocytes: derivation from the normally untranslated 5' region of the c-akt proto-oncogene activated by long terminal repeat.细胞毒性T淋巴细胞识别的BALB/c RL雄性1白血病排斥抗原肽：源自由长末端重复序列激活的c-akt原癌基因正常未翻译的5'区域。
Cancer Res. 1995 Nov 1;55(21):4780-3.
4
Diversity of epitopes recognized by cytotoxic T lymphocytes that are specific for rejection antigen peptide pRL1a presented on BALB/c leukemia RL Male 1.由细胞毒性T淋巴细胞识别的表位的多样性，这些细胞毒性T淋巴细胞对在BALB/c白血病RL雄性1上呈递的排斥抗原肽pRL1a具有特异性。
Int Immunol. 1997 Aug;9(8):1195-201. doi: 10.1093/intimm/9.8.1195.
5
Production of murine leukemia RLmale1 rejection antigen peptide pRL1a by proteolysis of natural precursor pRL1b.通过天然前体pRL1b的蛋白水解作用产生鼠白血病RLmale1排斥抗原肽pRL1a。
Jpn J Cancer Res. 1996 Nov;87(11):1165-70. doi: 10.1111/j.1349-7006.1996.tb03127.x.
6
Murine leukemia RL male 1 and sarcoma Meth A antigens recognized by cytotoxic T lymphocytes (CTL).细胞毒性T淋巴细胞（CTL）识别的小鼠白血病RL雄性1型和肉瘤Meth A抗原。
Cancer Sci. 2003 Nov;94(11):931-6. doi: 10.1111/j.1349-7006.2003.tb01380.x.
7
Vaccination with multiple antigen peptide as rejection antigen peptide in murine leukemia.以多抗原肽作为排斥抗原肽对小鼠白血病进行疫苗接种。
Cancer Res. 1998 May 1;58(9):1960-4.
8
Occurrence of tumor antigen pRL1a specific CD8 T cells in spleen cells from syngeneic BALB/c, semiallogeneic (BALB/c x C57BL/6)F1 and allogeneic C57BL/6 mice.同基因BALB/c、半同种异体（BALB/c×C57BL/6）F1和同种异体C57BL/6小鼠脾细胞中肿瘤抗原pRL1a特异性CD8 T细胞的出现情况。
Int J Oncol. 2002 May;20(5):1019-25.
9
Analysis of CD8 T-cell response by IFNgamma ELISPOT and H-2L(d)/pRL1a tetramer assays in pRL1a multiple antigen peptide-immunized and RL male 1-bearing BALB/c and (BALB/c x C57BL/6) F(1) mice.在经pRL1a多抗原肽免疫的以及携带RL雄性1的BALB/c和（BALB/c×C57BL/6）F(1)小鼠中，通过IFNγ ELISPOT和H-2L(d)/pRL1a四聚体分析对CD8 T细胞反应进行分析。
Cancer Sci. 2004 Mar;95(3):254-9. doi: 10.1111/j.1349-7006.2004.tb02212.x.
10
Transforming activity of the RL-akt gene, a c-akt gene activated by long terminal repeat insertion in murine leukemia RL(male symbol)1 cells.RL-akt基因的转化活性，该基因是一种在鼠白血病RL（雄性符号）1细胞中因长末端重复序列插入而激活的c-akt基因。
Mol Carcinog. 1999 Dec;26(4):286-97.

引用本文的文献

1
Defects in antigen processing and presentation: mechanisms, immune evasion and implications for cancer vaccine development.抗原加工与呈递缺陷：机制、免疫逃逸及对癌症疫苗研发的影响
Nat Rev Immunol. 2025 Aug 8. doi: 10.1038/s41577-025-01208-8.
2
The landscape of T cell antigens for cancer immunotherapy.癌症免疫治疗的 T 细胞抗原全景。
Nat Cancer. 2023 Jul;4(7):937-954. doi: 10.1038/s43018-023-00588-x. Epub 2023 Jul 6.
3
Toward Establishing an Ideal Adjuvant for Non-Inflammatory Immune Enhancement.为非炎症性免疫增强建立理想佐剂。
Cells. 2022 Dec 11;11(24):4006. doi: 10.3390/cells11244006.
4
Understanding small ORF diversity through a comprehensive transcription feature classification.通过全面的转录特征分类来理解小 ORF 多样性。
DNA Res. 2021 Sep 13;28(5). doi: 10.1093/dnares/dsab007.
5
Antitumour dendritic cell vaccination in a priming and boosting approach.树突状细胞瘤苗接种在初步免疫和加强免疫中的应用。
Nat Rev Drug Discov. 2020 Sep;19(9):635-652. doi: 10.1038/s41573-020-0074-8. Epub 2020 Aug 6.
6
Comprehensive profiling of translation initiation in influenza virus infected cells.流感病毒感染细胞中翻译起始的综合分析。
PLoS Pathog. 2019 Jan 23;15(1):e1007518. doi: 10.1371/journal.ppat.1007518. eCollection 2019 Jan.
7
Exploiting non-canonical translation to identify new targets for T cell-based cancer immunotherapy.利用非规范翻译鉴定 T 细胞为基础的癌症免疫治疗的新靶标。
Cell Mol Life Sci. 2018 Feb;75(4):607-621. doi: 10.1007/s00018-017-2628-4. Epub 2017 Aug 19.
8
Immune-mediated antitumor effect by type 2 diabetes drug, metformin.2型糖尿病药物二甲双胍的免疫介导抗肿瘤作用。
Proc Natl Acad Sci U S A. 2015 Feb 10;112(6):1809-14. doi: 10.1073/pnas.1417636112. Epub 2015 Jan 26.
9
Non-conventional sources of peptides presented by MHC class I.MHC Ⅰ类分子呈递的非经典来源肽。
Cell Mol Life Sci. 2011 May;68(9):1471-9. doi: 10.1007/s00018-011-0655-0. Epub 2011 Mar 10.
10
Effective adoptive therapy of tap-deficient lymphoma using diverse high avidity alloreactive T cells.利用多种高亲和力同种反应性 T 细胞对 Tap 缺陷性淋巴瘤进行有效的过继性治疗。
Cancer Immunol Immunother. 2010 Apr;59(4):629-33. doi: 10.1007/s00262-009-0805-5. Epub 2009 Dec 18.

本文引用的文献

1
ANTIGENIC SPECIFICITY OF BENZO(A)PYRENE-INDUCED SARCOMAS.苯并（a）芘诱发肉瘤的抗原特异性
J Natl Cancer Inst. 1964 Jun;32:1229-43. doi: 10.1093/jnci/32.6.1229.
2
Demonstration of resistance against methylcholanthrene-induced sarcomas in the primary autochthonous host.在原发性本地宿主中对甲基胆蒽诱导的肉瘤产生抗性的证明。
Cancer Res. 1960 Dec;20:1561-72.
3
Immunity to methylcholanthrene-induced sarcomas.对甲基胆蒽诱导肉瘤的免疫性。
J Natl Cancer Inst. 1957 Jun;18(6):769-78.
4
A transplantable mast-cell neoplasm in the mouse.一种可移植的小鼠肥大细胞瘤。
J Natl Cancer Inst. 1957 Apr;18(4):587-601.
5
Antigenic properties of methylcholanthrene-induced tumors in mice of the strain of origin.甲基胆蒽诱发的原种系小鼠肿瘤的抗原特性。
Cancer Res. 1953 Dec;13(12):835-7.
6
The proteins encoded by c-akt and v-akt differ in post-translational modification, subcellular localization and oncogenic potential.c-akt和v-akt编码的蛋白质在翻译后修饰、亚细胞定位和致癌潜力方面存在差异。
Oncogene. 1993 Jul;8(7):1957-63.
7
Structure, expression and chromosomal mapping of c-akt: relationship to v-akt and its implications.c-akt的结构、表达及染色体定位：与v-akt的关系及其意义
Oncogene. 1993 Mar;8(3):745-54.
8
The tyrosinase gene codes for an antigen recognized by autologous cytolytic T lymphocytes on HLA-A2 melanomas.酪氨酸酶基因编码一种抗原，该抗原可被HLA - A2黑色素瘤上的自体细胞溶解性T淋巴细胞识别。
J Exp Med. 1993 Aug 1;178(2):489-95. doi: 10.1084/jem.178.2.489.
9
A nonpolymorphic major histocompatibility complex class Ib molecule binds a large array of diverse self-peptides.一种非多态性的主要组织相容性复合体Ib类分子结合大量不同的自身肽段。
J Exp Med. 1994 Feb 1;179(2):579-88. doi: 10.1084/jem.179.2.579.
10
Lysis of ras oncogene-transformed cells by specific cytotoxic T lymphocytes elicited by primary in vitro immunization with mutated ras peptide.通过用突变型ras肽进行初次体外免疫引发的特异性细胞毒性T淋巴细胞对ras癌基因转化细胞的裂解作用。
J Exp Med. 1994 Feb 1;179(2):473-9. doi: 10.1084/jem.179.2.473.

文献AI研究员

20分钟写一篇综述，助力文献阅读效率提升50倍。

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

文档翻译

学术文献翻译模型，支持多种主流文档格式。

立即体验